Group items tagged

American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division. Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division. He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into UK community pharmacies. As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small multiple operators) can be fully understood and supported.

The Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that Ozempic has been found at two UK wholesalers on 18 October. The pre-filled falsely labelled pens have been purchased from legitimate suppliers in Austria and Germany. However, there has been no evidence that fake Ozempic has been supplied to UK patients. Dr Alison Cave, MHRA Chief Safety Officer spoke about closely with regulatory partners to ensure patients' safety. He said: "Buying semaglutide from illegally trading online suppliers significantly increases the risk of getting a product either falsified or not licensed for use in the UK. "Products purchased in this way will not meet our strict quality and safety standards, and taking such medicines may put your health at risk," he added.

The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year. Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK. The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024. For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK. The Department of Health and Social Care (DHSC) believes that thousands of men's lives could be saved each year if prostate cancer is detected early with effective screening methods.

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK. MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK. It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer. RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted. The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is "no progress in improving diagnosis rates." At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed. Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations. Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.

Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry, which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK. The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout each module. A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am. NPA calls for funding to boost pharmacy resilience Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.

Opella Healthcare, trading as Sanofi Consumer Healthcare, said it has entered into a dual partnership agreement with Alliance Healthcare and Phoenix Healthcare Distribution for the wholesale supply of its products to UK pharmacies. In effect from the start of February, the new dual partnership will ensure Sanofi Consumer Healthcare 'continues to provide its customers with exceptional customer service', the company said, adding that the increased efficiency will facilitate improved service levels and stock availability of Cialis Together, Allevia, Buscopan, Dulcolax and Phenergan to community pharmacies in the UK. "At Sanofi Consumer Healthcare we are committed to supporting the self-care agenda in the UK," Nick Linton, head of UK country operations, commented. "Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond. Our new wholesale model reflects our deep commitment to working as efficiently as possible in close partnership with pharmacists to shape a healthier future."

Erectile dysfunction (ED), also known as impotence, is characterized by the consistent or recurrent inability to achieve and/or maintain an erection sufficient for sexual intercourse. It becomes increasingly common with age, affecting approximately 50 - 55 per cent of men aged between 40 and 70 years. ED is estimated to affect up to three-quarters of men globally, and by 2025, 322 million men are expected to experience it. Research indicates that erectile dysfunction is highly prevalent in the UK, affecting over a quarter of younger men. Among Brits with ED, cardiometabolic and psychological conditions were frequently observed. Despite the high prevalence of erectile dysfunction among men, it remains poorly understood, underdiagnosed, and undertreated.

Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England. Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab. "I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire. Those who have not been vaccinated are "eight times more likely to get into hospital," he warned. The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

The UK Health Security Agency on Friday said it had designated a sub-lineage of the dominant and highly transmissible Omicron coronavirus variant as a variant under investigation. BA.2, which does not have the specific mutation seen with Omicron that can be used as a proxy to easily distinguish it from Delta, is being investigated but has not been designated a variant of concern. "It is the nature of viruses to evolve and mutate, so it's to be expected that we will continue to see new variants emerge," Dr Meera Chand, incident director at the UKHSA, said. "Our continued genomic surveillance allows us to detect them and assess whether they are significant." Britain had identified 53 sequences of the BA.2 sub-lineage as of January 10, with updated figures due to be published later on Friday.

An international specialty pharmaceutical group, Essential Pharma has announced the completion of two transactions with fellow UK-based Rosemont Pharmaceuticals. The company completed the divestment of its oral liquid portfolio to Rosemont, and acquired a series of attractive, niche products with "geographic expansion potential." Commenting on the announcement, Essential Pharma chief executive Steen Vangsgaard said: "The Rosemont products bring additional niche products into our portfolio with international expansion potential. "The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international specialty pharma platform." Under the divestment deal, Rosemont Pharmaceuticals will acquire the product portfolio of licences, registrations and trademarks, as well as related commercial rights, to a number of oral generic products which are used to treat a range of conditions in various therapeutic areas.

In a recent survey of 2,000 UK adults, 34 per cent preferred consulting pharmacists for health advice after researching symptoms, while for those surveyed specifically from Wales, this figure increased to 35 per cent, according to 2San - a global supplier of healthcare products and solutions. The survey said women had a higher tendency, with 39 per cent seeking their pharmacist's guidance compared to 29 per cent of men surveyed. According to the survey findings, over one-fifth of people in the UK are turning to pharmacists instead of their primary care physician or doctor for guidance and advice with medical symptoms. "With more than 38 million patients in the UK waiting more than two weeks for a GP appointment, it is unsurprising that 34 per cent of people surveyed asked a pharmacist for advice over their primary care physician/doctor in the last 12 months," 2san said. In Wales, over a third of people prefer their community pharmacist for support and advice, while those aged 65 and above still tend to consult their primary care physician.

The Royal Pharmaceutical Society has stated that the UK Commission on Pharmacy Professional Leadership lacks the essential transparency, efficiency, and diligence needed for success, urging a shift in its approach. The Commission's operational approach hinders its ability to meet the expectations of both the profession and the public, while prioritising government interests over their needs and preferences, RPS Chief Executive Paul Bennett (R) and President Claire Anderson have jointly said. In a blog post on September 7, the RPS leaders asserted that the Commission lacks transparency and is progressing slowly in implementing proposals that were published seven months ago. "Most pharmacy leaders are growing frustrated and increasingly impatient with the Commission's perceived lack of "meaningful progress" in enhancing leadership within the field," the pair noted. In June 2022, the four UK Chief Pharmaceutical Officers (CPhOs) formed an independent Commission with leadership expertise drawn from various domains, both within and outside of pharmacy, to assess the future of professional leadership. The Pharmacy Minister Neil O'Brien recently revealed that the Commission's costs, funded by the offices of the CPhOs, amounted to £87,745.

Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK. Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities. Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever 10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever. These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes.

New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence. UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases. "Those who have never received a measles vaccine (MMR) are at risk," said UKHSA. MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward. Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s ('Wakefield cohorts') and some may still not be fully vaccinated. As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.

Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals. Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic. The honours were announced on Thursday (13). Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019. He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar markets and spearheaded its operations in the US.

Phoenix UK has partnered with 2San Global Ltd, a diagnostic and digital tools company, to supply home testing kits to its 5,200 independent pharmacy members through Numark and selected Rowlands Pharmacy branches nationwide. Both Numark and Rowlands Pharmacy are owned by Phoenix. Numark will be the first UK wholesaler to supply 2San's home tests, granting members swift access to these screening products for essential health insights in minutes, all at reasonable prices, the company said in a statement. Numark will offer 10 essential tests to its 5,200 independent pharmacy members from August, while Rowlands Pharmacy will provide a selection of tests in over 380 branches beginning September. This collaboration aligns with Phoenix's goal of improving diagnostic accessibility and easing strain on the NHS.